Medical condition
Prostate Cancer
Prostate Cancer is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- cabazitaxel (CABAZITAXEL ACCORD) Antineoplastic and immunomodulating agents (L01)
- abiraterone acetate (ABIRATERONE KRKA) Antineoplastic and immunomodulating agents (L02)
- docetaxel (DOCETAXEL ACCORD) Antineoplastic and immunomodulating agents (L01)
- denosumab (CORORA) Musculo-skeletal system (M05)
- enzalutamide (XTANDI) Antineoplastic and immunomodulating agents (L02)
- darolutamide (NUBEQA) Antineoplastic and immunomodulating agents (L02)
- olaparib (LYNPARZA) Antineoplastic and immunomodulating agents (L01)
- apalutamide (ERLYAND) Antineoplastic and immunomodulating agents (L02)
- relugolix (ORGOVYX) Systemic hormonal preparations (H01)
- radium ra223 dichloride (XOFIGO) Various (V10)
- autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-t) (PROVENGE) Antineoplastic and immunomodulating agents (L03)
- degarelix (FIRMAGON 120MG) Antineoplastic and immunomodulating agents (L02)
Latest Prostate Cancer news
FDA Approves Capivasertib for PTEN-Deficient Prostate Cancer
FDA Approves Capivasertib for PTEN-Deficient prostate cancer, expanding TRUQAP into a new oncology setting. The approval pairs capivasertib with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive disease.
Pfizer sharpens prostate cancer case with Talzenna win — oncology
Pfizer announced a Phase III win for Talzenna (talazoparib) plus Xtandi (enzalutamide) in metastatic castration-sensitive prostate cancer, setting up a potential broader label. This analysis covers the TALAPRO-3 results, implications for the prostate cancer treatment landscape, and key milestones for pharma teams and investors.
New Hormone Regimen Shows Promise for Prostate Cancer Surgery Patients: Study Insights
ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
Structured plan for ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
Candel's Prostate Cancer Drug: Long-Term Data Insights Ahead of FDA Filing
Candel Therapeutics is poised to file its prostate cancer drug, CAN-2409, with the FDA following positive long-term Phase 3 data. This analysis explores the clinical and commercial implications for the pharmaceutical industry.
FDA Advisory Committee Recommends AstraZeneca's TRUQAP for PTEN-Deficient Prostate Cancer
FDA Advisory Committee votes 7-1 to recommend AstraZeneca's TRUQAP (capivasertib) for PTEN-deficient metastatic hormone-sensitive prostate cancer patients.